Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors
- 1 January 2003
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 21 (16) , 1135-1152
- https://doi.org/10.2165/00019053-200321160-00001
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial)The American Journal of Cardiology, 2002
- Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialThe Lancet, 2001
- Costs and effects of combining stenting and abciximab (ReoPro®) in daily practiceInternational Journal of Cardiology, 2001
- Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non???ST-Segment Elevation Acute Coronary SyndromesPharmacoEconomics, 2001
- Economic Evaluation of Enoxaparin Sodium versus Heparin in Unstable AnginaPharmacoEconomics, 2000
- Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trialThe Lancet, 1999
- Cost-Effectiveness Analysis of Enoxaparin versus Unfractionated Heparin for Acute Coronary SyndromesPharmacoEconomics, 1999
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988
- Release of Prostaglandins and Thromboxane into the Coronary Circulation in Patients with Ischemic Heart DiseaseNew England Journal of Medicine, 1981